At the same time, the molecular and cellular changes might be induced in breast cancer cells in the presence of CD133+ HPCs have not been uncovered,the follow-up experimental plan of our research group is to identify possible pathways of action and study the changes of pathway which effected by the antibodies that act on CD133 + targets. The gene discussed is PROM1; the disease is breast carcinoma.